Tuesday, July 30, 2019 3:04:51 AM
2nd line pancreatic cancer phase 2 pivotal Precision Promise is going to start Q3. The goal with Precision Promise is to start
A.)monotherapy SM-88 first in 2nd line PC patients
B.) then SM-88/chemo combo for 1st line PC patients soon after 2nd line starts
Q3 of 2019 is July - September of 2019. That means these pivotal studies are intended to be started between these months, pending there is no type of delay.
Final prostate cancer phase 2 data is expected 2nd half of 2019
Update On TYME-18 IND expected 2nd half of 2019
Preclinical data using SM-88 for 15 cancer types expected 2nd half of 2019.
FEATURED Element79 Gold Corp. Announces Sale of 100% Interest in Elder Creek, North Mill Creek, and Elephant Projects to 1472886 B.C. Ltd. • Sep 9, 2024 9:34 AM
North Bay Resources Commences Gold Shipments, Fran Gold Project, British Columbia; Enters Taber Gold Mine JV, Sierra County, California • NBRI • Sep 9, 2024 9:15 AM
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM
Reliant Coffee Debuts at #271 on the Inc. 5000 List of Fastest Growing Companies - Coffee Service Industry Disruptor Brews Up Exponential Growth Sep 5, 2024 11:51 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • MFL • Sep 4, 2024 9:02 AM